Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R (2) between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer.

[1]  J. Ajani,et al.  Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Wieand,et al.  Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[4]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[5]  T. Hickish,et al.  Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Galle,et al.  CPT11/FA/5-FU versus ELF in chemonaive patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[8]  Yoon-Koo Kang,et al.  Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[10]  D. Sargent,et al.  Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Fleming,et al.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. , 1985, JAMA.

[12]  C. Bokemeyer,et al.  Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Kurek,et al.  Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Buyse,et al.  Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  WRITING COMMITTEE , 2009 .

[16]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[17]  Satoshi Morita,et al.  Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. , 2013, European journal of cancer.

[18]  J. Ajani,et al.  Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Rufibach,et al.  Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Tae Won Kim,et al.  A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-fu (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC) , 2001 .

[21]  Woo Ick Yang,et al.  A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy , 2011, Cancer.

[22]  U. Haglund,et al.  Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  E. Cho,et al.  Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  B. Dörken,et al.  Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[26]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[27]  E. Van Cutsem,et al.  Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Zaluski,et al.  Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[30]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Wein,et al.  Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer , 2005, British Journal of Cancer.

[33]  Y. Bang,et al.  Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Zaluski,et al.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Kurihara,et al.  Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. , 2004, Anticancer research.

[36]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Lavin,et al.  An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Ychou,et al.  Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  S. Yoshida,et al.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.